KEVIN GAREY to Feces
This is a "connection" page, showing publications KEVIN GAREY has written about Feces.
Connection Strength
2.671
-
Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. Antimicrob Agents Chemother. 2025 Feb 13; 69(2):e0125124.
Score: 0.751
-
Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of Clostridium difficile From Stool Samples. Ann Lab Med. 2015 May; 35(3):306-13.
Score: 0.381
-
A quantitative PCR to detect non-toxigenic Clostridioides difficile. Microbiol Spectr. 2025 Jan 07; 13(1):e0160824.
Score: 0.186
-
Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence. Clin Infect Dis. 2023 12 05; 77(Suppl 6):S487-S496.
Score: 0.174
-
Stool Interleukin-1? Differentiates Clostridioides difficile Infection (CDI) From Asymptomatic Carriage and Non-CDI Diarrhea. Clin Infect Dis. 2023 02 08; 76(3):e1467-e1475.
Score: 0.164
-
Heterogeneity and lyophilization comparison of stool processing for gastrointestinal bile acid measurement by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Jan 01; 1214:123569.
Score: 0.162
-
Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe. 2021 Aug; 70:102387.
Score: 0.146
-
Clostridioides difficile ribotypes isolated from domestic environment and from patients in Bangladesh. Anaerobe. 2019 Apr; 56:88-90.
Score: 0.125
-
Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis. 2013 Apr; 56(7):1059-60.
Score: 0.081
-
Automated system to identify Clostridium difficile infection among hospitalised patients. J Hosp Infect. 2009 Aug; 72(4):337-41.
Score: 0.064
-
Donor-recipient specificity and age-dependency in fecal microbiota therapy and probiotic resolution of gastrointestinal symptoms. NPJ Biofilms Microbiomes. 2023 08 03; 9(1):54.
Score: 0.042
-
Redefining Clostridioides difficile infection antibiotic response and clinical outcomes. Lancet Infect Dis. 2023 07; 23(7):e259-e265.
Score: 0.042
-
Higher In Vivo Fecal Concentrations of Clostridioides difficile Toxins A and B in Patients With North American Pulsed-Field Gel Electrophoresis Type 1/Ribotype 027 Strain Infection. Clin Infect Dis. 2022 11 30; 75(11):2019-2022.
Score: 0.040
-
Stool Toxin Concentration Does Not Distinguish Clostridioides difficile Infection from Colonization in Children Less Than 3 Years of Age. J Pediatric Infect Dis Soc. 2022 Oct 25; 11(10):454-458.
Score: 0.040
-
Ultrasensitive and Quantitative Toxin Measurement Correlates With Baseline Severity, Severe Outcomes, and Recurrence Among Hospitalized Patients With Clostridioides difficile Infection. Clin Infect Dis. 2022 07 06; 74(12):2142-2149.
Score: 0.039
-
A multisite genomic epidemiology study of Clostridioides difficile infections in the USA supports differential roles of healthcare versus community spread for two common strains. Microb Genom. 2021 06; 7(6).
Score: 0.036
-
Clostridioides difficile Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes. Clin Infect Dis. 2021 05 18; 72(10):e460-e465.
Score: 0.036
-
Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection. Gut Microbes. 2021 Jan-Dec; 13(1):1-18.
Score: 0.035
-
Fusobacteriumnucleatum Adheres to Clostridioides difficile via the RadD Adhesin to Enhance Biofilm Formation in Intestinal Mucus. Gastroenterology. 2021 03; 160(4):1301-1314.e8.
Score: 0.035
-
Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. Infect Control Hosp Epidemiol. 2018 11; 39(11):1322-1329.
Score: 0.030
-
A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob. 2016 Apr 12; 15:22.
Score: 0.026
-
Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol. 2014 Apr; 21(4):509-17.
Score: 0.022
-
A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol. 2006 May; 101(5):1112-6.
Score: 0.013